Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...

AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including ...

NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) decreased during the last reporting period, falling from 384.09K to 213.07K. This put 0.56% of the company's publicly available shares short.

After reaching an important support level, Xilio Therapeutics, Inc. (XLO) could be a good stock pick from a technical perspective. XLO recently experienced a "golden cross" event, which saw its 50 ...

AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...